Related Experiment Video
Updated: Dec 3, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.9K
Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction
Danielle L Kirkman1, Natalie Bohmke1, Hayley E Billingsley1
1Department of Kinesiology and Health Sciences, College of Humanities & Sciences, Virginia Commonwealth University, Richmond, VA, United States.
Frontiers in Endocrinology
|October 29, 2020
Summary
Heart failure with preserved ejection fraction (HFpEF) is a growing epidemic with no approved treatments. Sarcopenic obesity (SO) is common in HFpEF, worsening outcomes and exercise intolerance.
Area of Science:
- Cardiovascular Medicine
- Gerontology
- Metabolic Disorders
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a significant public health concern with a rapidly increasing prevalence.
- Currently, no FDA-approved therapies exist to improve health-related outcomes in HFpEF, representing a major unmet need in cardiovascular medicine.
- Aging and obesity are key features of HFpEF, leading to a high incidence of sarcopenic obesity (SO) within this patient population.
Purpose of the Study:
- To review the current understanding of pathophysiological mechanisms linking HFpEF and SO.
- To examine the clinical outcomes associated with SO in HFpEF patients.
- To discuss existing and potential therapeutic strategies for managing SO in HFpEF.
Main Methods:
- Literature review of pathophysiological mechanisms.
- Analysis of clinical outcomes and comorbidities associated with SO in HFpEF.
- Evaluation of current and prospective lifestyle and pharmaceutical interventions.
Main Results:
- Sarcopenic obesity (SO) is prevalent in HFpEF and linked to comorbidities, poorer cardiovascular health, increased hospitalizations, reduced quality of life, and higher mortality.
- SO significantly contributes to exercise intolerance, a primary symptom in HFpEF.
- Existing research highlights the complex interplay between aging, obesity, muscle loss, and cardiovascular dysfunction in HFpEF.
Conclusions:
- SO is a critical factor in HFpEF pathophysiology and clinical presentation.
- Targeting SO presents a promising avenue for novel therapeutic strategies in HFpEF.
- Further research is urgently needed to elucidate the multifaceted mechanisms of SO in HFpEF and develop effective interventions.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
441
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
441
01:17Pathophysiology of Heart Failure
2.3K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.3K
01:27Heart Failure I: Introduction
482
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
482
01:26Heart Failure III: Clinical Manifestations
272
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
272
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
224
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
224
01:30Heart Failure VII: Nursing Interventions
285
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
285